Article
Hematology
F. Karl, C. Liang, R. Boettcher-Loschinski, A. Stoll, C. Flamann, S. Richter, C. Lischer, S. Voelkl, B. Jacobs, M. Boettcher, R. Jitschin, H. Bruns, T. Fischer, E. Holler, W. Roesler, T. Dandekar, A. Mackensen, D. Mougiakakos
Summary: Allo-SCT is a curative treatment for hematologic malignancies, relying on the graft-versus-leukemia (GVL) effect of donor T cells. Oxidative stress caused by DNA damage weakens the function of T cells and hampers the GVL effect. High levels of 8-hydroxydeoxyguanosine (8-OHdG), a biomarker for oxidative stress, were associated with enhanced T-cell activation, premature exhaustion, increased relapse risk, and shorter overall survival. Enhancing DNA repair in reconstituting T cells could improve GVL efficacy.
Article
Hematology
Misha C. Tran, Yasmin Hasan, Amy Wang, Kamil Yenice, Julien Partouche, Wendy Stock, Richard A. Larson, Satyajit Kosuri, James L. LaBelle, Justin Kline, Peter A. Riedell, Andrew S. Artz, Ralph Weichselbaum, Michael R. Bishop, Bulent Aydogan, Hongtao Liu
Summary: Relapse after allo-SCT is a common issue, and a second SCT can be considered for treatment. The study explored the feasibility of combining IM-TMI with fludarabine and melphalan for conditioning in patients undergoing a second or greater allo-SCT. The results showed that the combination therapy was feasible and achieved favorable outcomes.
Article
Immunology
Sakhila Ghimire, Daniela Weber, Katrin Hippe, Elisabeth Meedt, Matthias Hoepting, Anna-Sophia Kattner, Andreas Hiergeist, Andre Gessner, Carina Matos, Saroj Ghimire, Daniel Wolff, Matthias Edinger, Petra Hoffmann, Hendrik Poeck, Wolfgang Herr, Ernst Holler
Summary: The study found that the expression of GPR receptors was significantly upregulated in GvHD patients after allo-SCT and strongly correlated with FOXP3 and NLRP3 expression, but the use of broad-spectrum antibiotics suppressed this expression, interfering with the immune regulatory response.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Takayuki Inoue, Motoko Koyama, Katsuji Kaida, Kazuhiro Ikegame, Kathleen S. Ensbey, Luke Samson, Shuichiro Takahashi, Ping Zhang, Simone A. Minnie, Satoshi Maruyama, Shinichi Ishii, Takashi Daimon, Takahiro Fukuda, Hirohisa Nakamae, Takahide Ara, Yumiko Maruyama, Ken Ishiyama, Tatsuo Ichinohe, Yoshiko Atsuta, Bruce R. Blazar, Scott N. Furlan, Hiroyasu Ogawa, Geoffrey R. Hill
Summary: Administration of glucocorticoids before and after haplo-identical hematopoietic stem cell transplantation can effectively inhibit graft-versus-host disease, reduce relapse rates, and improve survival outcomes in patients with acute leukemia.
Article
Hematology
Viviane Gournay, Nicolas Vallet, Vivien Peux, Kristi Vera, Jennifer Bordenave, Marion Lambert, Aurelien Corneau, David Michonneau, Regis Peffault de Latour, Sophie Caillat-Zucman, Gerard Socie, Mathieu F. Chevalier
Summary: This study comprehensively characterized the immune cells in patients after allo-HSCT using mass cytometry, and identified certain features associated with relapse of AML, providing new insights for restoring anti-AML immunity.
Article
Immunology
Khalid Ali Nasif, Awad S. Al Samghan, Nahla El-Sharkawy, Amr M. Abass, Ebtesam Elgezawy, Safaa A. A. Khaled, Mahmoud Elbadry, Marwa M. Thabet
Summary: This study analyzed dendritic cells in PBSC grafts and found that higher donor DC1 counts were associated with the incidence of aGVHD, while DC2 counts were linked to relapse. Monitoring DC-graft may play a fundamental role in predicting aGVHD and disease relapse.
JOURNAL OF INFLAMMATION RESEARCH
(2022)
Review
Oncology
Yishan Ye, Luxin Yang, Xiaolin Yuan, He Huang, Yi Luo
Summary: Donor lymphocyte infusion (DLI) is a key strategy for treating AML relapse, but the prognosis remains poor. Recent advances in using novel targeted and immunomodulatory agents, as well as manipulation of DLI graft, have shown potential for improving treatment efficacy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Shideh Namazi Bayegi, Amir Ali Hamidieh, Maryam Behfar, Mahmood Bozorgmehr, Amene Saghazadeh, Nader Tajik, Ali-Akbar Delbandi, Farzaneh Tofighi Zavareh, Samaneh Delavari, Mehdi Shekarabi, Nima Rezaei
Summary: Reconstitution of T-cell subsets after allo-HSCT is critical for pathogen protection and preventing GvHD. CD4 and CD8 T-cells were higher 12 months after the transplant but still lower than in healthy controls and pre-transplant. Acute GvHD was associated with an increase in TEMRA cells in CD4 T-cells, while chronic GvHD was associated with a decrease in Th1 cells in CD4 T-cells and effector memory cells in CD8 T-cells.
IMMUNOLOGY LETTERS
(2023)
Review
Hematology
Steffen T. Simon, Anne Pralong, Michael Hallek, Christoph Scheid, Udo Holtick, Marco Herling
Summary: Patients undergoing allogeneic stem cell transplantation (allo-SCT) require supportive and palliative care, with common issues being fatigue and psychological distress, while chronic GvHD significantly impacts quality of life. There is a lack of research on further issues related to allo-SCT.
ANNALS OF HEMATOLOGY
(2021)
Review
Immunology
Benjamin Watkins, Kirsten M. Williams
Summary: Severe acute and chronic graft versus host disease (GVHD) is a major cause of morbidity and mortality after hematopoietic cell transplantation. Certain drugs can reduce the risk of GVHD, but they come with potential risks of relapse, graft failure, infections, and delayed immune reconstitution. However, these drugs have expanded donor options, especially for non-Caucasian individuals who previously had limited transplant options.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Zhangjie Chen, Sisi Zhen, Tingting Zhang, Yuyan Shen, Aiming Pang, Donglin Yang, Rongli Zhang, Qiaoling Ma, Yi He, Jialin Wei, Weihua Zhai, Xin Chen, Erlie Jiang, Mingzhe Han, Sizhou Feng
Summary: In this study, the efficacy and safety of VEN+HMA and IC in treating hematological relapse after allo-HSCT were compared. The results showed that there were no significant differences in overall response and survival between the two groups. However, VEN+HMA was associated with a lower incidence of adverse events and aGvHD. Further research is needed to improve long-term survival.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Frederic Baron, Myriam Labopin, Johanna Tischer, Fabio Ciceri, Anna Maria Raiola, Didier Blaise, Simona Sica, Jan Vydra, Renato Fanin, Friedrich Stolzel, Alessandro Busca, Jose Luis Diez-Martin, Yener Koc, Arnon Nagler, Mohamad Mohty
Summary: This study analyzed the impact of stem cell source on leukemia-free survival (LFS) in adult patients with AML undergoing HLA-haploidentical transplantation. The results showed that for patients aged 55 and above, using bone marrow as the stem cell source resulted in lower non-relapse mortality (NRM) and better LFS. In contrast, for younger patients, using peripheral blood stem cells (PBSC) resulted in at least comparable LFS.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Chemistry, Physical
Andre Grishin, Bruno Berini, Maxime Vallet, Simon Hurand, Florian Maudet, Corinne Sartel, Mathieu Fregnaux, Sophie Nowak, Gaelle Amiri, Said Hassani, Damien Aureau, Vincent Sallet, Valerie Demange, Yves Dumont
Summary: This study focuses on the direct liquid injection Atomic Layer Deposition (ALD) of TiO2 films with thicknesses of a few nanometers. The researchers propose and demonstrate the effectiveness of 2-dimensional (2D) [Ca2Nb3O10]- and [Ti0.865O2]0.54-nanosheets as seeds for the crystallization and epitaxy of ultra-thin TiO2 films. Furthermore, they find that the structure of the 2D nanosheets determines the growth orientation of the epitaxial anatase, providing potential applications in opto-electronics.
APPLIED SURFACE SCIENCE
(2023)
Article
Hematology
Ziheng Xu, Jaebok Choi, Matthew Cooper, Jeffrey King, Mark A. Fiala, Jingxia Liu, Iskra Pusic, Rizwan Romee, Amanda Cashen, Meagan A. Jacoby, Keith Stockerl-Goldstein, Camille Abboud, Ravi Vij, Geoffrey Uy, Peter Westervelt, Matthew J. Walter, John F. Dipersio, Mark A. Schroeder
Summary: This study aimed to determine the maximum tolerated dose (MTD) of azacitidine (AZA) and its impact on graft-versus-host disease (GVHD) and chronic GVHD (cGVHD) after hematopoietic cell transplantation (HCT). The results showed that the efficacy of AZA in preventing GVHD was limited, but it may have a beneficial effect in preventing disease relapse.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Review
Immunology
Nadir Kadri, Sylvie Amu, Ellen Iacobaeus, Erik Boberg, Katarina Le Blanc
Summary: This review summarizes the experience from clinical trials in the field of graft versus host disease (GvHD) and highlights the challenges in predicting the efficacy of mesenchymal stromal cells (MSCs) in alleviating GvHD. It emphasizes the importance of considering individual patient characteristics and immune biomarkers in determining MSC responsiveness.
CELLULAR & MOLECULAR IMMUNOLOGY
(2023)
Article
Cell Biology
Marco Romano, Raul Elgueta, Daniel McCluskey, Ana Maria Ortega-Prieto, Emilie Stolarczyk, Francesco Dazzi, Baltasar Lucendo-Villarin, Jose Meseguer-Ripolles, James Williams, Giorgia Fanelli, David C. Hay, Fiona M. Watt, Giovanna Lombardi
Summary: Regenerative medicine aims to replace damaged tissues by stimulating tissue repair or transplanting cells. Pluripotent stem cells have the potential for unlimited cell production, making them valuable for regenerative medicine. However, immune responses pose a challenge to success. This study investigates the immunological properties of human pluripotent stem cell-derived hepatocyte-like cells and shows their potential for in vitro immunoregulation.
Article
Biophysics
Alice Pievani, Valentina Granata, Giacomo Desantis, Laura Antolini, Sara Ornaghi, Antonio Galleu, Andrea Biondi, Bernhard Gentner, Francesco Dazzi, Marta Serafini
Summary: Monocytes are effective at improving engraftment in HSPC transplantation, particularly in cases of limited cell doses such as CB transplantation and HSC gene therapy. Co-culturing monocytes increases survival and stemness of CB-CD34(+) cells. Soluble factors and direct-cell contact interactions play critical roles in the HSC-monocyte crosstalk.
BONE MARROW TRANSPLANTATION
(2022)
Article
Immunology
Astrid Beerlage, Karoline Leuzinger, Luca Valore, Roby Mathew, Till Junker, Beatrice Drexler, Jakob R. Passweg, Hans H. Hirsch, Joerg Halter
Summary: Patients after allogeneic stem cell transplantation generally have a good response to mRNA vaccines against SARS-CoV-2, but there is still a proportion of patients with inadequate vaccination response, which can be improved after a third vaccination despite immunosuppressive therapy.
TRANSPLANT INFECTIOUS DISEASE
(2022)
Article
Hematology
Yves Chalandon, Giulia Sbianchi, Luuk Gras, Linda Koster, Jane Apperley, Jenny Byrne, Urpu Salmenniemi, Henrik Sengeloev, Mahmoud Aljurf, Grzegorz Helbig, Francesca Kinsella, Goda Choi, Peter Remenyi, John A. Snowden, Marie Robin, Stig Lenhoff, Stephan Mielke, Jakob Passweg, Annoek E. C. Broers, Nicolaus Kroeger, Zeynep Arzu Yegin, Sen Mui Tan, Patrick J. Hayden, Donal P. McLornan, Ibrahim Yakoub-Agha
Summary: With the introduction of TKI, the number of allo-HCT for CP CML patients has decreased significantly. The use of 1, 2, or 3 TKI prior to allo-HCT does not affect the overall survival, progression-free survival, relapse incidence, or non-relapse mortality. However, the disease stage and KPS score significantly influence the survival and progression-free survival, emphasizing the importance of careful candidate selection and performing allo-HCT during CP1 phase.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Till Junker, Thomas Volken, Gregor Stehle, Beatrice Drexler, Laura Infanti, Andreas Buser, Jakob Passweg, Stefan Schaub, Michael Dickenmann, Joerg Halter, Andreas Holbro
Summary: This study reports the use of heparin as an alternative anticoagulant for immunoadsorption (IA) in the preparation of ABO blood group-incompatible living donor kidney transplantation (ABOi LDKT). Results showed that IA with heparin was safe and effective, with no major bleeding or significant complications observed. Graft function, graft survival, and overall survival did not significantly differ from standard anticoagulation or ABO compatible recipients.
TRANSFUSION MEDICINE AND HEMOTHERAPY
(2023)
Article
Biophysics
Claire Seydoux, Chakradhara Rao Satyanarayana Uppugunduri, Michael Medinger, Tiago Nava, Joerg Halter, Dominik Heim, Yves Chalandon, Urs Schanz, Gayathri Nair, Nathan Cantoni, Jakob R. Passweg, Marc Ansari
Summary: This study investigated the correlation between GSTA1 gene polymorphisms and Bu pharmacokinetics in 60 adult patients receiving allo-HCT with BuCyBu or CyBu conditioning regimens. The results showed that patients with GSTA1*B*B polymorphisms had significantly higher Bu-AUC compared to those with GSTA1*A*A polymorphisms, and there was a significant correlation with Bu clearance. Patients with lower AUC values may have lower non-relapse mortality (NRM).
BONE MARROW TRANSPLANTATION
(2023)
Letter
Oncology
Zuleika Calderin Sollet, Antonia Schafer, Sylvie Ferrari-Lacraz, Stavroula Masouridi-Levrat, Anne-Claire Mamez, Amandine Pradier, Federico Simonetta, Yves Chalandon, Jean Villard, Stephane Buhler
Article
Virology
Marie-Celine Zanella, Diem-Lan Vu, Krisztina Hosszu-Fellous, Dionysios Neofytos, Chistian Van Delden, Lara Turin, Antoine Poncet, Federico Simonetta, Stavroula Masouridi-Levrat, Yves Chalandon, Samuel Cordey, Laurent Kaiser
Summary: Metagenomics identified previously unrecognized viruses in allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients, highlighting their potential as sources of infection. This observational cohort study aimed to investigate the prevalence and dynamics of DNA and RNA viruses in the plasma of allo-HSCT recipients for one year post-transplant. TTV infection was observed in 97% of patients, followed by HPgV-1 (prevalence: 26-36%). Viral loads for TTV and HPgV-1 peaked at month 3. Multiple Polyomaviridae viruses were detected in over 10% of patients. HPyV6 and HPyV7 had a prevalence of 27% and 12% respectively at month 3, while CMV had a prevalence of 27%. The other viruses had low prevalence rates, and co-infections were observed in 72% of patients at month 3. Further research is needed to understand the relationship between these viral infections, immune reconstitution, and clinical outcomes.
Article
Immunology
Lara Chavaz, Lena Royston, Stavroula Masouridi-Levrat, Anne-Claire Mamez, Federica Giannotti, Sarah Morin, Christian Van Delden, Yves Chalandon, Dionysios Neofytos
Summary: In this single-center study, we found a 23% incidence of clinically significant CMV infection during the first 100 days after discontinuation of letermovir prophylaxis in 61 allogeneic HCT recipients. This infection mainly occurred in haploidentical HCT recipients and was not associated with CMV-DNAemia under letermovir.
OPEN FORUM INFECTIOUS DISEASES
(2023)
Review
Immunology
Chiara Giacomini, Cecilia Graneli, Ryan Hicks, Francesco Dazzi
Summary: Mesenchymal stromal cells (MSCs) have shown good safety but mixed efficacy in the treatment of various clinical conditions. The heterogeneity of cell preparations, lack of mechanistic understanding, and poorly defined criteria for patient stratification have hindered informative clinical trials. However, studies have shown that apoptotic MSCs can be phagocytosed by anti-inflammatory cells, suggesting that the activation state of cytotoxic T or NK cells can be used as a biomarker for predicting clinical responses to MSC treatment. MSCs can orchestrate inflammatory responses through different mechanisms, including cell-contact and inflammatory cytokine-mediated licensing.
CELLULAR & MOLECULAR IMMUNOLOGY
(2023)
Article
Biophysics
Xavier Poire, Myriam Labopin, Emmanuelle Polge, Arnold Ganser, Gerard Socie, Tobias Gedde-Dahl, Edouard Forcade, Juergen Finke, Yves Chalandon, Claude-Eric Bulabois, Ibrahim Yakoub-Agha, Mahmoud Aljurf, Nicolaus Kroeger, Igor Wolfgang Blau, Arnon Nagler, Jordi Esteve, Mohamad Mohty
Summary: Allogeneic hematopoietic cell transplantation remains the best consolidation strategy for acute myeloid leukemia with complex karyotype. AML with pure hyperdiploid karyotype may have a distinct prognosis after allo-HCT compared to non-pure hyperdiploid CK AML.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Biophysics
Silvio Ragozzino, Nicolas J. Mueller, Dionysios Neofytos, Jakob Passweg, Antonia Mueller, Michael Medinger, Christian Van Delden, Stavroula Masouridi-Levrat, Yves Chalandon, Sarah Tschudin-Sutter, Nina Khanna, Swiss Transplant Cohort Study
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Simone Dertschnig, Peter Gergely, Jurgen Finke, Urs Schanz, Ernst Holler, Udo Holtick, Gerard Socie, Michael Medinger, Jakob Passweg, Takanori Teshima, Christos Stylianou, Stephan Oehen, Dominik Heim, Christoph Bucher
Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative option for patients with acute myelogenous leukemia, but outcomes are limited by leukemia relapse, graft-versus-host disease (GVHD), and abnormal immune reconstitution. Mocravimod, an oral sphingosine-1-phosphate receptor modulator, shows potential in preventing GVHD while maintaining graft-versus-leukemia (GVL) activity. This study evaluated the safety, tolerability, and pharmacokinetics of mocravimod in allo-HSCT recipients and found that it can be safely added to standard treatment regimens without negative impact on engraftment and transplantation outcomes.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Oncology
Franziska C. Adam, Jakub Szybinski, Jorg P. Halter, Nathan Cantoni, Friedel Wenzel, Katharina Leonards, Sime Brkic, Jakob R. Passweg, Ivo Touw, Julia E. Maxson, Sara C. Meyer
Summary: This study investigates the role of co-occurring germline and somatic CSF3R mutations in chronic neutrophilic leukemia (CNL) and the impact of clonal evolution on leukemia transformation. The study finds that CNL can transform not only to acute myeloid leukemia (AML) but also to mixed phenotype acute leukemia (MPAL). The molecular evolution is particularly interesting with germline and somatic mutations occurring on the same allele.
